Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neoplasms, Basal Cell Clear all
Enrolling by invitation Phase 2 Interventional Accepts healthy volunteers

Ultralow Dose PET Imaging of 18F-FDOPA

NCT07542158
View directory record Official record
Conditions
Heathy Volunteer, Parkinsonian Syndromes, Neuroendocrine (NE) Tumors, Gliomas
Interventions
18F-FDOPA
Drug
Lead sponsor
Akiva Mintz
Other
Eligibility
18 Years to 120 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Englewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 23, 2026, 11:09 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Outcomes Mandate National Integration With Cannabis as Medicine

NCT03944447
View directory record Official record
Conditions
Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Interventions
Cannabis, Medical, RYAH-Medtech Inhaler
Drug · Device
Lead sponsor
OMNI Medical Services, LLC
Network
Eligibility
7 Years and older
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
17
States / cities
Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Jul 23, 2026, 11:09 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Biological Sample Collection for Research and Biobanking

NCT04270604
View directory record Official record
Conditions
Parkinson Disease, Diabetes Mellitus, Type 1, Macular Degeneration, ALS, Cancer, Alzheimer Disease, Huntington Disease
Interventions
Biological sample collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
1 Month to 100 Years
Enrollment
1,279 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Jul 23, 2026, 11:09 PM EDT
Completed Phase 2 Interventional Results available

A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study

NCT00959647
View directory record Official record
Conditions
Ovarian Cancer, Basal Cell Carcinoma, Metastatic Colorectal Cancer
Interventions
Vismodegib, FOLFOX, FOLFIRI, Bevacizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
10
States / cities
Scottsdale, Arizona • Oakland, California • Palm Springs, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 23, 2026, 11:09 PM EDT
Completed Phase 1 Interventional

Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors

NCT00880308
View directory record Official record
Conditions
Advanced Solid Tumor Cancers, Medulloblastoma, Basal Cell Carcinoma
Interventions
LDE225
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Jul 23, 2026, 11:09 PM EDT
Not listed Phase 1 Interventional

Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer

NCT03775525
View directory record Official record
Conditions
Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach, Lymphoma, Sarcoma, Cutaneous T Cell Lymphoma, Head and Neck Squamous Cell Carcinoma, Basal Cell Carcinoma, Cutaneous T-cell Lymphoma, Cutaneous Squamous Cell Carcinoma
Interventions
GZ17-6.02, Capecitabine
Drug
Lead sponsor
Genzada Pharmaceuticals USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Scottsdale, Arizona • Los Angeles, California • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Jul 23, 2026, 11:09 PM EDT
Completed Phase 2 Interventional

Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma

NCT04669808
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
STP705
Drug
Lead sponsor
Sirnaomics
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Jul 23, 2026, 11:09 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes

NCT01700049
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
vismodegib (150 mg PO daily)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Jul 23, 2026, 11:09 PM EDT
Not yet recruiting Phase 4 Interventional

Impact of Dysport on PMFF Donor Scar

NCT07720726
View directory record Official record
Conditions
Skin Cancer Excision Site, Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma
Interventions
Abobotulinumtoxin-A, Control- Saline injection
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 23, 2026, 11:09 PM EDT
Completed Not applicable Interventional

Video-Based Treatment Options for Basal Cell Carcinoma

NCT02158650
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
Video-Based Informed Consent
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 16, 2015 · Synced Jul 23, 2026, 11:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage

NCT00314756
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
imiquimod
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Jul 23, 2026, 11:09 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome

NCT06050122
View directory record Official record
Conditions
Gorlin Syndrome
Interventions
Patidegib Topical Gel, Patidegib Topical Gel with no active patidegib
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
24
States / cities
Rogers, Arkansas • Fremont, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jul 23, 2026, 11:09 PM EDT
Completed Phase 1 Interventional

Optimizing Photodynamic Therapy of Cutaneous Neoplastic Diseases Via Structured Illumination and Real-time Dosimetry.

NCT00784108
View directory record Official record
Conditions
Skin Cancer, Signs and Symptoms
Interventions
Modulated Imaging (MI), Photodynamic therapy
Device · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Jul 23, 2026, 11:09 PM EDT
Completed Phase 2 Interventional

Docetaxel in Treating Patients With Solid Tumors

NCT00003565
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Head and Neck Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
docetaxel
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2008
U.S. locations
72
States / cities
Anniston, Alabama • La Jolla, California • San Diego, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Jul 23, 2026, 11:09 PM EDT
Completed Not applicable Interventional

Isotretinoin in Preventing Skin Cancer

NCT00025012
View directory record Official record
Conditions
Melanoma (Skin), Non-melanomatous Skin Cancer
Interventions
isotretinoin
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
2 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Jul 23, 2026, 11:09 PM EDT
Completed Phase 1 Interventional

Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer

NCT00079300
View directory record Official record
Conditions
Non-melanomatous Skin Cancer
Interventions
imiquimod, conventional surgery
Drug · Procedure
Lead sponsor
National Naval Medical Center
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2013 · Synced Jul 23, 2026, 11:09 PM EDT
Not yet recruiting Not applicable Interventional

Machine Learning Analysis of Two-photon Fluorescence Microscopy of Dermatologic Biopsies

NCT07682831
View directory record Official record
Conditions
Basal Cell Carcinoma of Skin, Squamous Cell Carcinoma (Skin)
Interventions
Two photon microscopy imaging
Device
Lead sponsor
University of Rochester
Other
Eligibility
Not listed
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Victor, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 23, 2026, 11:09 PM EDT
Completed Not applicable Interventional

Effectiveness and Safety of X A-DERM™ Microsurfaced Acellular Dermal Matrix for Wound Healing After MOHS Surgery

NCT06919809
View directory record Official record
Conditions
Wound Healing After MMS Surgery, BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma, Melanoma In Situ
Interventions
A microsurfaced ADM (acellular dermal matrix)
Device
Lead sponsor
McGuire Institute
Industry
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rockwall, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jul 23, 2026, 11:09 PM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of Oral Midazolam for Perioperative Anxiety Relief of Patients Undergoing Mohs Micrographic Surgery

NCT00578214
View directory record Official record
Conditions
Basal Cell Carcinoma, Squamous Cell Carcinoma, Skin Cancer, Anxiety
Interventions
Randomized Midazolam, Placebo, Local Anesthesia, Prospective Midazolam
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 8, 2012 · Synced Jul 23, 2026, 11:09 PM EDT
Completed Not applicable Interventional

Laser Treatment of Basal Cell Carcinoma Under Imaging Guidance

NCT05138328
View directory record Official record
Conditions
Carcinoma, Basal Cell
Interventions
Treatment of basal cell carcinoma with Nd:YAG laser under imaging guidance of optical coherence tomography (OCT)
Device
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 105 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 14, 2025 · Synced Jul 23, 2026, 11:09 PM EDT
Terminated Phase 2 Interventional Results available

Oral ONC201 in Adult Recurrent Glioblastoma

NCT02525692
View directory record Official record
Conditions
Glioblastoma, Diffuse Midline Glioma, H3 K27M Glioma, Thalamic Glioma, Infratentorial Glioma, Basal Ganglia Glioma
Interventions
Dordaviprone (ONC201)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
16 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
5
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2024 · Synced Jul 23, 2026, 11:09 PM EDT
Completed Phase 3 Interventional

Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer

NCT00006799
View directory record Official record
Conditions
Anorexia, Cachexia, Head and Neck Cancer, Quality of Life
Interventions
megestrol acetate, quality-of-life assessment
Drug · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Jul 23, 2026, 11:09 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors

NCT00014456
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
Interventions
filgrastim, docetaxel, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Jul 23, 2026, 11:09 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma

NCT01835626
View directory record Official record
Conditions
Locally Advanced Basal Cell Carcinoma, Skin Cancer, Cutaneous Malignancy
Interventions
Vismodegib, Radiation therapy
Drug · Radiation
Lead sponsor
Sue Yom
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Jul 23, 2026, 11:09 PM EDT